MorphoSys AG (MOR)

My several thoughts about $HGEN and recently announced participation in the BET trial ("big effect trial") funded by NIAID.
1) Lenzilumab selection was based on the compassionate use data, not on the data from the ongoing ph3 trial. This might implicate that probably no interim report data from the ongoing ph3 trial is available, which in turn might implicate that HGEN has problems with fast patients enrolment (similarly to CYDY).
2) It is strange why now a new ph3 trial is started (with 100 patients in each arm) when another ph3 trial (with 300 patients) is already running (started already in May). The novelty regarding this new trial is that a combination of remdesivir+lenzilumab is tested as well.
3) Actually I do not understand why this BET trial with lenzilumab (and not only with lenzilumab) has not started several months ago as soon as promising data from compassionate use has been available. At the same time (around April-May) several other arms of such trial could have been added, including leronlimab from $CYDY (targeting CCR5) or other monoclonal antibodies targeting the same cytokine (GM-CSF) as lenzilumab - i.e. mavrilimumab from $KNSA, otilimab from $MOR / $GSK, and gimsilumab from Roivant.
4) Of course it is a good news for HGEN that NIH is interested in lenzilumab and a bad news for CYDY if leronlimab has not been considered (but this might change). But anyway, if the data from the current leronlimab trials is positive (especially in case that the S/C trial is halted by the ethical committee), there is surely no need to start a new, NIAID funded trial.

If $EXEL is looking to diversify & add molecules in the clinic quickly w/ premier bi-specific Ab, then it needs to look into collaboration w/ $XNCR .Their collaboration with Genentech $RHHB Janssen $amgn $NVS
MDAnderson morphosys $MOR Alexion $alxn Astellas (Japan) validates XNCR's technology. It's at least worth a look and there could be hugely beneficial arrangements for both parties. Xencor has very rich pipeline already and I am sure would be happy to have a partner take over some of these advanced molecules as well as with their excellent and much sought after bi-specific technology and premiere engineering platform, have many in early preclinical development. Doesn't mean EXEL needs to jump in but some due diligence and potential partnership would be time well spent. Bi-specific technology of biologics would nicely complement Exelixis' small molecule and ADC pipeline and collaborations.

This is a very strong downtrend - that started end of 2020. I am pretty sure this downtrend will continue through 2022. I would not recommend to anybody to invest here - even with this promising pipeline - and I am invested in MOR - unfortunately.

The continuous drop in MOR has nothing to do with short positions anymore. The short rate does not change much.

There have been also a lot of talk about MOR is a takeover candidate. I have to laugh - why should anyone buy MOR for 30euros or so. In 1-2 years MOR can be bought for less then 10 euros. But I doubt that even then someone would be interested.

The CEO has done a terrible job - just fact - spending almost 1 billion. Not sure what he was thinking.
The only one who is trying to work for the investors is the CFO. Buying shares - giving statements etc..

Friendly advise - just stay away from this stock.